Skip to main content
SpringerLink
Log in

Hematopoietic cell transplantation for mantle cell lymphoma

  • Review Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Hematopoietic cell transplantation (HCT) represents a valuable therapeutic option for younger patients with mantle cell lymphoma (MCL). Despite the rarity of this disease, significant research efforts have been undertaken to improve the outcomes, and autologous HCT is currently considered an established treatment for younger patients who respond to induction therapy. The past 20 years have seen further progress by incorporating rituximab and high-dose cytarabine into induction therapy and adopting rituximab as posttransplant maintenance therapy. Allogeneic HCT is generally reserved for relapsed/refractory patients because of concerns about high toxicities; however, a fraction of relapsed/refractory patients can be salvaged at the expense of high non-relapse mortality. Although significant advances have been attained over the past decades, MCL treatment still has room for improvement. A risk-adapted approach based on measurable residual disease and genetic information will promote therapeutic optimization and individualization. Moreover, the recent development of molecularly targeted drugs is expected to alter the therapeutic landscape, and the incorporation of novel drugs into the current treatment scheme is another key issue. These ongoing and future advances will change the role of HCT in MCL treatment and contribute to further improvements in outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Leux C, Maynadie M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, et al. Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014;93:1327–33.

    PubMed  Google Scholar 

  4. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.

    PubMed  Google Scholar 

  5. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790–5.

    PubMed  Google Scholar 

  6. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–8.

    PubMed  Google Scholar 

  7. Abrisqueta P, Scott DW, Slack GW, Steidl C, Mottok A, Gascoyne RD, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28:2489–95.

    CAS  PubMed  Google Scholar 

  8. Cohen JB, Han X, Jemal A, Ward EM, Flowers CR. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122:2356–63.

    CAS  PubMed  Google Scholar 

  9. Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM. Limited-stage mantle-cell lymphoma. Ann Oncol. 2003;14:1555–61.

    CAS  PubMed  Google Scholar 

  10. Dabaja BS, Zelenetz AD, Ng AK, Tsang RW, Qi S, Allen PK, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017;28:2185–90.

    CAS  PubMed  Google Scholar 

  11. Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62–71.

    CAS  PubMed  Google Scholar 

  12. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984–92.

    CAS  PubMed  Google Scholar 

  13. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565–75.

    CAS  PubMed  Google Scholar 

  14. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150:200–8.

    CAS  PubMed  Google Scholar 

  15. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156:346–53.

    CAS  PubMed  Google Scholar 

  16. Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24:1587–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944–53.

    CAS  PubMed  Google Scholar 

  18. Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19:1449–58.

    CAS  PubMed  Google Scholar 

  19. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

    CAS  PubMed  Google Scholar 

  20. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013;31:1442–9.

    CAS  PubMed  Google Scholar 

  21. Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15–23.

    PubMed  Google Scholar 

  22. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367:520–31.

    CAS  PubMed  Google Scholar 

  23. Cortelazzo S, Ponzoni M, Ferreri AJM, Dreyling M. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2020;153:103038.

    PubMed  Google Scholar 

  24. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211–23.

    CAS  PubMed  Google Scholar 

  25. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105:2677–84.

    CAS  PubMed  Google Scholar 

  26. Zoellner AK, Unterhalt M, Stilgenbauer S, Hubel K, Thieblemont C, Metzner B, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8:e648–57.

    PubMed  Google Scholar 

  27. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37:471–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112:2687–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410–8.

    CAS  PubMed  Google Scholar 

  30. Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018.

  31. Merryman RW, Edwin N, Redd R, Bsat J, Chase M, LaCasce A, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4:858–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176:759–69.

    CAS  PubMed  Google Scholar 

  33. Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, et al. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv. 2019;3:3132–5.

    PubMed  PubMed Central  Google Scholar 

  34. Kolstad A, Laurell A, Jerkeman M, Gronbaek K, Elonen E, Raty R, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123:2953–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250–60.

    PubMed  Google Scholar 

  36. Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol. 2019;94:E50–3.

    PubMed  Google Scholar 

  37. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol. 2009;27:4365–70.

    CAS  PubMed  Google Scholar 

  38. Ladetto M, Cortelazzo S, Ferrero S, Evangelista A, Mian M, Tavarozzi R, et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8:e34–44.

    PubMed  Google Scholar 

  39. Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, et al. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020;95:583–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Doorduijn JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, Bohmer LH, Minnema MC, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020;190:385–93.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Le Gouill S, Beldi-Ferchiou A, Alcantara M, Cacheux V, Safar V, Burroni B, et al. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. Lancet Haematol. 2020;7:e798–807.

    PubMed  Google Scholar 

  42. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27:6101–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood. 2013;121:48–53.

    CAS  PubMed  Google Scholar 

  44. Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al. A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173:89–95.

    CAS  PubMed  Google Scholar 

  45. Zelenetz AD, Gordon LI, Arbramson JS, Advani RH, Bartlett NL, Elizabeth Budde L, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 5.2021. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 11 Nov 2021.

  46. Okamoto M, Kusumoto S. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). Int J Hematol. 2020;111:5–15.

    PubMed  Google Scholar 

  47. Riedell PA, Hamadani M, Ahn KW, Litovich C, Murthy GSG, Locke FL, et al. Outcomes and utilization trends of front-line autologous hematopoietic cell transplantation for mantle cell lymphoma. Transplant Cell Ther. 2021;27(911):e1–7.

    Google Scholar 

  48. Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, et al. Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia. 2016;30:1428–30.

    CAS  PubMed  Google Scholar 

  49. Peterlin P, Leux C, Gastinne T, Roland V, Mahe B, Dubruille V, et al. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation. 2012;94:295–301.

    PubMed  Google Scholar 

  50. Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, et al. Total body irradiation is safe and similarly effective as chemotherapy-only conditioning in autologous stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant. 2018;24:282–7.

    CAS  PubMed  Google Scholar 

  51. Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, et al. Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1403–6.

    PubMed  PubMed Central  Google Scholar 

  52. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol. 2014;32:273–81.

    PubMed  Google Scholar 

  53. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407–12.

    CAS  PubMed  Google Scholar 

  54. Maris MB, Sandmaier BM, Storer BE, Chauncey T, Stuart MJ, Maziarz RT, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–42.

    CAS  PubMed  Google Scholar 

  55. Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, et al. Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. Br J Haematol. 2019;184:999–1005.

    CAS  PubMed  Google Scholar 

  56. Kruger WH, Hirt C, Basara N, Sayer HG, Behre G, Fischer T, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). Ann Hematol. 2021;100:1569–77.

    PubMed  PubMed Central  Google Scholar 

  57. Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2018;53:617–24.

    CAS  PubMed  Google Scholar 

  58. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19:625–31.

    PubMed  PubMed Central  Google Scholar 

  59. Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, et al. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Cancer. 2015;121:3709–16.

    CAS  PubMed  Google Scholar 

  60. Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903–10.

    CAS  PubMed  Google Scholar 

  61. Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol. 2019;184:1006–10.

    CAS  PubMed  Google Scholar 

  62. Dietrich S, Tielesch B, Rieger M, Nickelsen M, Pott C, Witzens-Harig M, et al. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Cancer. 2011;117:1901–10.

    PubMed  Google Scholar 

  63. Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol. 2014;25:1053–8.

    CAS  PubMed  Google Scholar 

  64. Riedell PA, Hamadani M, Ahn KW, Litovich C, Brunstein CG, Cashen AF, et al. Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. Br J Haematol. 2021. 195:757–763. https://doi.org/10.1111/bjh.17865.

    Article  CAS  PubMed  Google Scholar 

  65. Yamasaki S, Chihara D, Kim SW, Izutsu K, Iwato K, Fukuda T, et al. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. Ann Hematol. 2018;97:1445–52.

    CAS  PubMed  Google Scholar 

  66. Nordstrom L, Sernbo S, Eden P, Gronbaek K, Kolstad A, Raty R, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma—a Nordic Lymphoma Group study. Br J Haematol. 2014;166:98–108.

    PubMed  PubMed Central  Google Scholar 

  67. Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604–11.

    CAS  PubMed  Google Scholar 

  68. Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008;49:2081–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, et al. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow transplant research, and european society for blood and marrow transplantation clinical practice recommendations for transplantation and cellular therapies in mantle cell lymphoma. Transplant Cell Ther. 2021;27:720–8.

    PubMed  PubMed Central  Google Scholar 

  71. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215–23.

    CAS  PubMed  Google Scholar 

  72. Liu H, Johnson JL, Koval G, Malnassy G, Sher D, Damon LE, et al. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012;97:579–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, et al. Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant. 2016;22:380–5.

    PubMed  Google Scholar 

  74. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Cell Therapy, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan

    Masamitsu Yanada & Kazuhito Yamamoto

Authors
  1. Masamitsu Yanada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhito Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masamitsu Yanada.

Ethics declarations

Conflict of interest

MY received research funding from AbbVie, AstraZeneca, Celgene, Chugai, Eisai, IQVIA/Genmab, IQVIA/Incyte, Mundipharma, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Solasia Pharma, SymBio, Takeda, Yakult, and Zenyaku. KY received research funding from AbbVie, AstraZeneca, Celgene, Chugai, Eisai, HUYA/IQVIA Services Japan, IQVIA/Genmab, IQVIA/Incyte, Meiji Seika Pharma, Micron, Mundipharma, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Solasia Pharma, SymBio, Takeda, Yakult, and Zenyaku; consulting fees from Meiji Seika Pharma; and honoraria from AbbVie, ADC Therapeutics, AstraZeneca, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, HUYA/IQVIA Services Japan, Janssen, Kyowa Kirin, Meiji Seika Pharma, MSD, Nippon Shinyaku, Novartis, Ono Pharmaceutical, Otsuka Pharmaceutical, Sanofi, Stemline Therapeutics, SymBio, Takeda, Yakult, and Zenyaku.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanada, M., Yamamoto, K. Hematopoietic cell transplantation for mantle cell lymphoma. Int J Hematol 115, 301–309 (2022). https://doi.org/10.1007/s12185-022-03294-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-022-03294-z

Keywords

Search

Navigation